Disease and treatment related risk factors associated with poor neurocognitive domains (Table 4):
Age at diagnosis/initiation of therapy did not affect the neurocognitive scores. The entire cohort of patients received either prophylactic or therapeutic cranial radiotherapy(RT). The presence of CNS disease would entail receiving higher dose of RT to the neuralaxis. Receiving higher doses of RT to the neuralaxis was also not associated with poorer FSIQs. Chemotherapy protocol received did not have a directder age at assessment was associated impact on neurocognitive function. Giving higher doses of intravenous methotrexate or cytarabine or using triple IT over IT methotrexate was not associated with increased neurocognitive deficits(OR: 1.0 , 95% CI 0.3-3.5, p 1.000).